Automated cytochemistry in the prediction of remission following chemotherapy of patients with de novo acute myeloblastic leukemia

American Journal of Clinical Pathology
P WinkelN I Nissen

Abstract

In seven patients with de novo acute myeloblastic leukemia, the concentration of large unstained cells (LUC) in peripheral blood and the ratio between this quantity and the concentration of lymphocytes (LUC/LYMPH) were measured at short intervals during each patient's clinical course. An automated differential analyzer (the Hemalog-D) was used. Both quantities were significantly higher 12 days after the institution of daunomycin and cytosine arabinoside chemotherapy (between first and second treatment series when all patients were pancytopenic) in three of the patients who did not achieve remission (mean LUC = 59 cells/microliter, mean LUC/LYMPH = 13.9), as compared with four of the patients who went into remission following two series of chemotherapy (mean LUC = 16 cells/microliter, mean LUC/LYMPH = 3.11).

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.